ImetelChat

I have asked HI on SA to comment, he is very knowledgeable re patent law. bp

Thanks Hunt, it actually wasn't my find. Hat tip to Richard on YMB for this one (and many others). bp

http://www.managingmds.com/index.php?option=com_continued&view=material&Itemid=1233&course=155&nocredit=1&token=8088070b040224e7fec0c66dd2ba4ae9 Likelihood of approval is extremely high. Note discussion of disease modification. Dr. Steensma does not emphasize the more stringent entry criterion for I...

Cheng, for the benefit of the board would you consider a dispassionate (and I mean dispassionate) analysis of this paper and how this information might inform future combination studies? (If applicable at all.). Thanks, bp A non-natural nucleotide uses a specific pocket to selectively inhibit telome...

Kmall, of course! bp

Kmall since you have posted an excellent summary of the cc on YMB I will take that as implicit permission to re post here, thank you and keep up your "world travels"! Good morning board. During yesterdays call (which I was fortunate enough to have listened to twice) I took some notes to highlight wh...

Here's the link:

http://wsw.com/webcast/needham90/regist ... index.aspx

Superb presentation by Dr. Scarlett easily accessible via Gwen site. I will try to post link later if someone doesn’t do it first. bp

Kmall, I would love to see you take the record for "number of views". Keep up the good work! bp

That is my recollection as well. bp

Sargasso, thanks for responding. Actually I have to give Scarlett the benefit of the doubt. Yes the conference calls are frustrating since he only takes questions from the few remaining interested analysts. But the annual meeting has a different flavor. I think he really tries to answer questions si...

Sargasso, Way not ask Scarlett directly in May?

First off welcome new members and thank you for your contributions. As we approach the annual meeting, it is the one time when Dr. Scarlett actually takes questions from shareholders, my wife is insisting I go but I will probably not make the substantial trip especially if some of our Californians w...

Cheng, I think that fast track status conveys the privilege of more frequent meetings with the FDA and ongoing guidance regarding study design. This also allows for rolling submission of data. Even if the study design does not change from the original Janssen PIII, the FDA could confer an accelerate...

I always find the "fine print" which we all tend to gloss over, interesting. Looking back, there were allusions almost a year ago in the "forward looking statements", hints that Scarlett might go it alone with suggestions that Janssen may or may not continue the partnership etc. We know this all too...

Everyone is probably aware of the new board appointees. They are impressive and have been granted generous stipends and options, here's the link:

http://ir.geron.com/news-releases/news- ... rd-members

As board moderator I have set up some what I think are reasonable ground rules to keep discussions relevant and civil. I encourage in depth discussion but I will not allow ad hominem attacks. If you have differences with a poster's ideas, state your arguments but do not attack the individual himself...

Kmall, almost everyone with whom I have communicated and there have been many, who are interested in this drug, on the board or privately, has lost family and friends. I personally have been hit hard with the loss of family and Fish Sr and Irish became correspondence friends over several years time....

Welcome Kamall and best wishes for the success of your campaign. bp